Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity.
about
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsOptimising plasma levels of clozapine during metabolic interactions: a review and case report with adjunct rifampicin treatmentInsights into CYP2B6-mediated drug-drug interactionsIdentification of rifampin-regulated functional modules and related microRNAs in human hepatocytes based on the protein interaction networkEffects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteersAssessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.CYP2B6: new insights into a historically overlooked cytochrome P450 isozymeModest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteersEffect of renal impairment on the pharmacokinetics of bupropion and its metabolitesRapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men.Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavirUse of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseasesPolymorphic CYP2B6: molecular mechanisms and emerging clinical significance.Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymesPharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.Clinically significant drug interactions with newer antidepressants.Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems.Induction of cytochrome P450 enzymes: a view on human in vivo findings.Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism.Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjectsChiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19.Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers.Rifampicin markedly decreases the exposure to oral and intravenous tramadol.Toxicokinetics of isoeugenol in F344 rats and B6C3F1 mice.Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods.Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion.Induction of human cytochrome P450 3A4 by the irreversible myeloperoxidase inactivator PF-06282999 is mediated by the pregnane X receptor.The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity.Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects.
P2860
Q24631021-154E332D-9A36-4B63-8CD5-9152E1597A3FQ26799098-6DD63C90-AF83-4F3C-8D02-26E5F4A6AF22Q28078857-35566296-4780-4B23-845F-A297767567C1Q28597149-001B650B-F7D8-49EF-ADAC-21A5FC2F3E2AQ28750369-68B79DF2-40F1-486D-B764-6B67B98D1286Q30688345-BDC24C84-4456-4822-A5F8-4A8D84C2F710Q34116690-9E231BE4-6C71-4809-8F4E-1275B4B3C831Q34737523-AA87AD30-87A4-4D0B-8442-D31B44C2A086Q34824471-296DB2D2-CAA1-42B0-A88B-FF6515CF69F6Q35065867-1628245F-55EA-4706-B8B3-6C59A1D1C6FAQ36024598-2C64FF71-85A3-4827-93BC-918D0191E1F9Q36468142-B54E3BF4-61DD-4F6C-BF29-0F11BE8AC89BQ36593838-601A8E51-54C0-447A-B99A-37A59E85239AQ36733922-74D3046E-D38E-481F-8472-E02549581161Q36885659-C627BD98-71E7-47F0-9C35-92DABBB2E412Q37148882-3B84A7A3-A79A-4B8F-96B2-CD8010B46356Q37169244-BCC83140-575B-4052-826E-65B86B998544Q37186259-57A13F96-527D-4418-9897-5C67AB54FFA4Q37395740-4BFD16F0-2FE5-4AF4-9B38-B0C81B3C2699Q37968621-96C03A50-4224-4D5C-8194-31EDBE13DD9AQ38028549-5428CE2A-E138-429B-AC67-5799DAF0DA6DQ38057372-EB3AF37C-DFDB-40A1-8B58-41C50982CD9EQ38815352-70B5CC44-6CC9-4A94-B567-4609C9D090D2Q41153557-AFB66FFC-A640-4510-B860-8CA5588DB67AQ41791534-23B0785D-CE6A-4809-956D-0C3E2364136DQ42008173-FF5B05F0-0526-4A7C-B2BC-064ECBB97DA8Q42407006-D2C81033-1341-412E-8A78-2E610FD59366Q43042724-E8A248BF-9882-4B89-ACC4-7F044F4EDE36Q43183967-A04B8E65-25BE-470D-AE9F-F66E434A1F81Q43663355-C9F03E13-049C-40FD-8A91-2D7B9ECB3F69Q43685299-AC855687-1856-44C6-BFC2-8B941744E08DQ43908823-82645A9A-FD8B-4C9B-9A48-5E129C2E2399Q45132328-7CBB6716-FF1A-457C-A08B-8721D66211D3Q46466256-3ACAB8B8-454C-49A8-8D8F-09FF0E4D47DFQ47267937-ACA8B90D-64AA-47C1-825F-C38B6C67EACEQ47449167-6AAD5360-F86B-4528-8D0E-F15D51461761Q48027985-40524929-02F7-4F4E-87E9-F1422F853A20Q50028945-B2135B63-F298-4FF4-B2B8-12C64D727B21Q51628497-84CB41DA-791C-4517-AF67-77A84199DA81Q53475844-16620D74-34C1-4352-B6DE-1D29579F0194
P2860
Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Cytochrome P450 2B6 activity a ...... ion by rifampin and ethnicity.
@ast
Cytochrome P450 2B6 activity a ...... ion by rifampin and ethnicity.
@en
type
label
Cytochrome P450 2B6 activity a ...... ion by rifampin and ethnicity.
@ast
Cytochrome P450 2B6 activity a ...... ion by rifampin and ethnicity.
@en
prefLabel
Cytochrome P450 2B6 activity a ...... ion by rifampin and ethnicity.
@ast
Cytochrome P450 2B6 activity a ...... ion by rifampin and ethnicity.
@en
P2093
P50
P1476
Cytochrome P450 2B6 activity a ...... ion by rifampin and ethnicity.
@en
P2093
Annette S Gross
Julia K Blievernicht
Katarzyna K Loboz
Kenneth M Williams
Winston S Liauw
P356
10.1016/J.CLPT.2006.03.010
P407
P577
2006-07-01T00:00:00Z